{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:09:49Z","timestamp":1783087789004,"version":"3.54.6"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["YDZJ202301ZYTS082"],"award-info":[{"award-number":["YDZJ202301ZYTS082"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bcp.2025.117116","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T21:11:50Z","timestamp":1751663510000},"page":"117116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Advanced strategies for targeting molecular pathways in Sj\u00f6gren\u2019s syndrome"],"prefix":"10.1016","volume":"241","author":[{"given":"Dongxue","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bcp.2025.117116_b0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/03009742.2017.1324909","article-title":"Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sj\u00f6gren\u2019s syndrome (secondary Sj\u00f6gren\u2019s syndrome) focusing on autoimmune rheumatic diseases","volume":"47","author":"Alani","year":"2018","journal-title":"Scand. J. Rheumatol."},{"issue":"45","key":"10.1016\/j.bcp.2025.117116_b0010","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.3346\/jkms.2020.35.e369","article-title":"The prevalence of Sj\u00f6gren's syndrome in rheumatoid arthritis patients and their clinical features","volume":"35","author":"Kim","year":"2020","journal-title":"J. Korean Med. Sci."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2025.117116_b0015","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000789","article-title":"Sj\u00f6gren\u2019s syndrome: state of the art on clinical practice guidelines","volume":"4","author":"Rom\u00e3o","year":"2018","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.bcp.2025.117116_b0020","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.rcreu.2020.12.007","article-title":"Sj\u00f6gren's syndrome: epidemiology and clinical manifestations","volume":"29","author":"Reyes Jaraba","year":"2022","journal-title":"Revista Colombiana De Reumatolog\u00eda"},{"issue":"25","key":"10.1016\/j.bcp.2025.117116_b0025","doi-asserted-by":"crossref","first-page":"e3766","DOI":"10.1097\/MD.0000000000003766","article-title":"Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use","volume":"95","author":"Fragkioudaki","year":"2016","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.bcp.2025.117116_b0030","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000443","article-title":"Patient burden of Sj\u00f6gren\u2019s: a comprehensive literature review revealing the range and heterogeneity of measures used in assessments of severity","volume":"3","author":"Hammitt","year":"2017","journal-title":"RMD Open"},{"issue":"9","key":"10.1016\/j.bcp.2025.117116_b0035","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.3390\/jcm9092821","article-title":"Understanding the complexity of sj\u00f6gren\u2019s syndrome: Remarkable progress in elucidating NF-\u03baB mechanisms","volume":"9","author":"Sisto","year":"2020","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117116_b0040","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/03009740701678712","article-title":"Estimation of the prevalence of primary Sj\u00f6gren's syndrome in two age\u2010different community\u2010based populations using two sets of classification criteria: the Hordaland Health Study","volume":"37","author":"Haugen","year":"2008","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.bcp.2025.117116_b0045","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF02802321","article-title":"Anti-Ro (SSA) and anti-La (SSB) antibodies in autoimmune rheumatic diseases","volume":"12","author":"Youinou","year":"1994","journal-title":"Clin. Rev. Allergy"},{"key":"10.1016\/j.bcp.2025.117116_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar3348","article-title":"Disturbance of cytokine networks in Sj\u00f6gren's syndrome","volume":"13","author":"Youinou","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2025.117116_b0055","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0198-8859(01)00253-1","article-title":"HLA class I and class II are both associated with the genetic predisposition to primary Sj\u00f6gren syndrome","volume":"62","author":"Loiseau","year":"2001","journal-title":"Hum. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117116_b0060","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/imr.12821","article-title":"Impaired B\u2010cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies","volume":"292","author":"Meffre","year":"2019","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2025.117116_b0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10238-021-00728-6","article-title":"Sj\u00f6gren\u2019s syndrome: a systemic autoimmune disease","volume":"22","author":"Negrini","year":"2022","journal-title":"Clin. Exp. Med."},{"issue":"2","key":"10.1016\/j.bcp.2025.117116_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105479","article-title":"Autoimmune epithelitis in primary Sj\u00f6gren's syndrome","volume":"90","author":"Desvaux","year":"2023","journal-title":"Joint Bone Spine"},{"issue":"2","key":"10.1016\/j.bcp.2025.117116_b0075","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2014.10.016","article-title":"Autoimmune thyroid disorders","volume":"14","author":"Antonelli","year":"2015","journal-title":"Autoimmun. Rev."},{"issue":"7","key":"10.1016\/j.bcp.2025.117116_b0080","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.3390\/jcm9072299","article-title":"Current state of knowledge on primary Sj\u00f6gren\u2019s syndrome, an autoimmune exocrinopathy","volume":"9","author":"Parisis","year":"2020","journal-title":"J. Clin. Med."},{"issue":"6\u20137","key":"10.1016\/j.bcp.2025.117116_b0085","doi-asserted-by":"crossref","first-page":"A430","DOI":"10.1016\/j.autrev.2011.11.006","article-title":"Menopause in patients with autoimmune diseases","volume":"11","author":"Sammaritano","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bcp.2025.117116_b0090","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.phrs.2018.01.009","article-title":"Metabolic syndrome, autoimmunity and rheumatic diseases","volume":"133","author":"Medina","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"16","key":"10.1016\/j.bcp.2025.117116_b0095","doi-asserted-by":"crossref","first-page":"8855","DOI":"10.3390\/ijms22168855","article-title":"Vitamin D deficiency, osteoporosis and effect on autoimmune diseases and hematopoiesis: a review","volume":"22","author":"De Martinis","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.bcp.2025.117116_b0100","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.3390\/jcm9093057","article-title":"Contributions of major cell populations to Sj\u00f6gren\u2019s syndrome","volume":"9","author":"Witas","year":"2020","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117116_b0105","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1573397112666160714164149","article-title":"Update on pathogenesis of Sjogren's syndrome","volume":"13","author":"Sandhya","year":"2017","journal-title":"Curr. Rheumatol. Rev."},{"issue":"3","key":"10.1016\/j.bcp.2025.117116_b0110","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrrheum.2018.1","article-title":"B cells in the pathogenesis of primary Sj\u00f6gren syndrome","volume":"14","author":"Nocturne","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bcp.2025.117116_b0115","doi-asserted-by":"crossref","unstructured":"M. Jourdan, N. Robert, M. Cren, C. Thibaut, C. Duperray, A. Kassambara, M. Cogn\u00e9, K. Tarte, B. Klein, J. Moreaux, Characterization of human FCRL4-positive B cells, 12(6) (2017) e0179793.","DOI":"10.1371\/journal.pone.0179793"},{"issue":"6","key":"10.1016\/j.bcp.2025.117116_b0120","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1084\/jem.20050879","article-title":"Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells","volume":"202","author":"Ehrhardt","year":"2005","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.bcp.2025.117116_b0125","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/intimm\/dxaa053","article-title":"Fc receptor-like 4 and 5 define human atypical memory B cells","volume":"32","author":"Li","year":"2020","journal-title":"Int. Immunol."},{"key":"10.1016\/j.bcp.2025.117116_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102439","article-title":"Gene expression profiling of epithelium-associated FcRL4+ B cells in primary Sj\u00f6gren's syndrome reveals a pathogenic signature","volume":"109","author":"Verstappen","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bcp.2025.117116_b0135","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9123794","article-title":"Pathogenetic mechanisms implicated in Sj\u00f6gren\u2019s syndrome lymphomagenesis: a review of the literature","author":"Stergiou","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2025.117116_b0140","doi-asserted-by":"crossref","unstructured":"I.C. Mouat, E. Goldberg, M.S. Horwitz, Age-associated B cells in autoimmune diseases, 79(8) (2022) 402.","DOI":"10.1007\/s00018-022-04433-9"},{"issue":"1","key":"10.1016\/j.bcp.2025.117116_b0145","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s12026-012-8365-8","article-title":"TLR7 drives accumulation of ABCs and autoantibody production in autoimmune-prone mice","volume":"55","author":"Rubtsov","year":"2013","journal-title":"Immunol. Res."},{"issue":"3","key":"10.1016\/j.bcp.2025.117116_b0150","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jleuko\/qiad135","article-title":"TLR7 activation of age-associated B cells mediates disease in a mouse model of primary Sj\u00f6gren's disease","volume":"115","author":"Punnanitinont","year":"2024","journal-title":"J. Leukoc. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117116_b0155","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1007\/s11357-024-01159-3","article-title":"Age-associated B cell infiltration in salivary glands represents a hallmark of Sj\u00f6gren's-like disease in aging mice","volume":"46","author":"Bagavant","year":"2024","journal-title":"GeroScience"},{"key":"10.1016\/j.bcp.2025.117116_b0160","doi-asserted-by":"crossref","unstructured":"D. Marinkovic, T. Marinkovic, Putative role of marginal zone B cells in pathophysiological processes, 92(3) (2020) e12920.","DOI":"10.1111\/sji.12920"},{"key":"10.1016\/j.bcp.2025.117116_b0165","doi-asserted-by":"crossref","unstructured":"A.B. Peck, C.Q. Nguyen, Early Covert Appearance of Marginal Zone B Cells in Salivary Glands of Sj\u00f6gren's Syndrome-Susceptible Mice: Initiators of Subsequent Overt Clinical Disease, 22(4) (2021).","DOI":"10.3390\/ijms22041919"},{"issue":"9","key":"10.1016\/j.bcp.2025.117116_b0170","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/eji.200636270","article-title":"Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells","volume":"36","author":"Fletcher","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bcp.2025.117116_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.611795","article-title":"Immunosuppressive mechanisms of regulatory B cells","volume":"12","author":"Catal\u00e1n","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117116_b0180","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1093\/rheumatology\/key332","article-title":"B cells in Sj\u00f6gren\u2019s syndrome: from pathophysiology to therapeutic target","volume":"60","author":"Mielle","year":"2021","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.bcp.2025.117116_b0185","doi-asserted-by":"crossref","first-page":"R118","DOI":"10.1186\/ar4571","article-title":"B cell subsets and dysfunction of regulatory B cells in IgG4-related diseases and primary Sj\u00f6gren's syndrome: the similarities and differences","volume":"16","author":"Lin","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"21","key":"10.1016\/j.bcp.2025.117116_b0190","doi-asserted-by":"crossref","first-page":"13229","DOI":"10.3390\/ijms232113229","article-title":"Molecular mechanisms linking inflammation to autoimmunity in Sj\u00f6gren\u2019s syndrome: identification of new targets","volume":"23","author":"Sisto","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117116_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-021-02632-6","article-title":"Correlation of peripheral CD4+ GranzB+ CTLs with disease severity in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"23","author":"Wang","year":"2021","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2025.117116_b0200","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/rheumatology\/keaa105","article-title":"Lymphopenia in primary Sj\u00f6gren's syndrome is associated with premature aging of na\u00efve CD4+ T cells","volume":"60","author":"Fessler","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.bcp.2025.117116_b0205","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13075-022-02811-z","article-title":"Circulating Th2 cell reduction and Th1\/Th2 imbalance are correlated with primary Sjogren\u2019s syndrome-associated interstitial lung disease","volume":"24","author":"Shi","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bcp.2025.117116_b0210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.995895","article-title":"Exploiting the role of T cells in the pathogenesis of Sj\u00f6gren\u2019s syndrome for therapeutic treatment","volume":"13","author":"An","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117116_b0215","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001442","article-title":"Association between T follicular helper cells and T peripheral helper cells with B-cell biomarkers and disease activity in primary Sj\u00f6gren syndrome","volume":"7","author":"Dupr\u00e9","year":"2021","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.bcp.2025.117116_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e15565","article-title":"Altered subgroups of regulatory T cells in patients with primary Sj\u00f6gren's syndrome","volume":"9","author":"Lin","year":"2023","journal-title":"Heliyon"},{"issue":"8","key":"10.1016\/j.bcp.2025.117116_b0225","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1136\/annrheumdis-2016-210788","article-title":"Multiomic disease signatures converge to cytotoxic CD8 T cells in primary Sj\u00f6gren\u2019s syndrome","volume":"76","author":"Tasaki","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.bcp.2025.117116_b0230","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.jaci.2016.01.024","article-title":"Cytometry by time-of-flight immunophenotyping identifies a blood Sj\u00f6gren's signature correlating with disease activity and glandular inflammation","volume":"137","author":"Mingueneau","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bcp.2025.117116_b0235","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.602823","article-title":"CD8+ T lymphocytes: crucial players in sj\u00f6gren\u2019s syndrome","volume":"11","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.bcp.2025.117116_b0240","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s40265-016-0659-z","article-title":"Treating the underlying pathophysiology of primary Sj\u00f6gren syndrome: recent advances and future prospects","volume":"76","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.bcp.2025.117116_b0245","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1002\/jcp.29593","article-title":"Janus kinase inhibitors: a therapeutic strategy for cancer and autoimmune diseases","volume":"235","author":"Hosseini","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bcp.2025.117116_b0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-9255-8-22","article-title":"Role of IL-33 in inflammation and disease","volume":"8","author":"Miller","year":"2011","journal-title":"J. Inflamm."},{"issue":"14","key":"10.1016\/j.bcp.2025.117116_b0255","first-page":"3117","article-title":"Interleukin-33 induces angiogenesis and vascular permeability through ST2\/TRAF6-mediated endothelial nitric oxide production","volume":"114","author":"Choi","year":"2009","journal-title":"Blood, the Journal of the American Society of Hematology"},{"issue":"12","key":"10.1016\/j.bcp.2025.117116_b0260","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.3390\/ijms21124297","article-title":"Advances in mast cell activation by IL-1 and IL-33 in Sj\u00f6gren\u2019s syndrome: promising inhibitory effect of IL-37","volume":"21","author":"Conti","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117116_b0265","unstructured":"J. Mofors, Risk Factors and Comorbidity in Primary Sj\u00f6gren\u2019s Syndrome, Karolinska Institutet (Sweden)2021."},{"key":"10.1016\/j.bcp.2025.117116_b0270","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1533335","article-title":"IL-33\/ST2 axis in diverse diseases: regulatory mechanisms and therapeutic potential","volume":"16","author":"Sheng","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2025.117116_b0275","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cca.2017.09.019","article-title":"Enhanced expression of NLRP3 inflammasome-related inflammation in peripheral blood mononuclear cells in Sj\u00f6gren's syndrome","volume":"474","author":"Kim","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bcp.2025.117116_b0280","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jaut.2018.02.010","article-title":"Systemic activation of NLRP3 inflammasome in patients with severe primary Sj\u00f6gren's syndrome fueled by inflammagenic DNA accumulations","volume":"91","author":"Vakrakou","year":"2018","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.bcp.2025.117116_b0285","doi-asserted-by":"crossref","DOI":"10.1111\/imr.13406","article-title":"Molecular mechanisms of emerging inflammasome complexes and their activation and signaling in inflammation and pyroptosis","volume":"329","author":"Pandey","year":"2025","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bcp.2025.117116_b0290","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-3-030-72029-2_3","article-title":"Mechanisms of secretory dysfunction in autoimmune Sj\u00f6gren\u2019s syndrome","author":"Saleh","year":"2021","journal-title":"Sj\u00f6gren's Syndrome and Oral Health: Disease Characteristics and Management of Oral Manifestations"},{"issue":"12","key":"10.1016\/j.bcp.2025.117116_b0295","doi-asserted-by":"crossref","DOI":"10.1002\/adbi.202300173","article-title":"Modes and mechanisms of salivary gland epithelial cell death in Sjogren's syndrome","volume":"7","author":"Zhou","year":"2023","journal-title":"Advanced Biology"},{"key":"10.1016\/j.bcp.2025.117116_b0300","doi-asserted-by":"crossref","unstructured":"E. Tinazzi, G. Patuzzo, C. Lunardi, Autoantigens and Autoantibodies in the Pathogenesis of Sj\u00f6gren\u2019s Syndrome, Sj\u00f6gren's Syndrome, Elsevier2016, pp. 141-156.","DOI":"10.1016\/B978-0-12-803604-4.00009-5"},{"issue":"Suppl 118","key":"10.1016\/j.bcp.2025.117116_b0305","first-page":"36","article-title":"Angiogenic T cells in primary Sj\u00f6gren\u2019s syndrome: a double-edged sword","volume":"37","author":"Alunno","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"issue":"11","key":"10.1016\/j.bcp.2025.117116_b0310","doi-asserted-by":"crossref","first-page":"7637","DOI":"10.1167\/iovs.14-15430","article-title":"Transgenic mouse models of corneal neovascularization: new perspectives for angiogenesis research","volume":"55","author":"Kather","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2025.117116_b0315","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.rdc.2008.08.004","article-title":"New concepts in the pathogenesis of Sj\u00f6gren's syndrome","volume":"34","author":"Delaleu","year":"2008","journal-title":"Rheum. Dis. Clin. N. Am."},{"issue":"8","key":"10.1016\/j.bcp.2025.117116_b0320","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","article-title":"Pathogenesis of autoimmune disease","volume":"19","author":"Pisetsky","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117116_b0325","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/rheumatology\/kez142","article-title":"Treatment of Sj\u00f6gren\u2019s syndrome: current therapy and future directions","volume":"60","author":"Fox","year":"2021","journal-title":"Rheumatology"},{"issue":"Supplement_6","key":"10.1016\/j.bcp.2025.117116_b0330","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keab466","article-title":"New developments in Sjogren\u2019s syndrome","volume":"60","author":"Thalayasingam","year":"2021","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.bcp.2025.117116_b0335","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/annrheumdis-2012-202754","article-title":"Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome","volume":"72","author":"Ciccia","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.bcp.2025.117116_b0340","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/rheumatology\/keu004","article-title":"Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"53","author":"Ciccia","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.bcp.2025.117116_b0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar4359","article-title":"Efficacy and safety of rituximab treatment in early primary Sj\u00f6gren's syndrome: a prospective, multi-center, follow-up study","volume":"15","author":"Carubbi","year":"2013","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2025.117116_b0350","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/art.37850","article-title":"Rituximab therapy for primary Sj\u00f6gren's syndrome: an open\u2010label clinical trial and mechanistic analysis","volume":"65","author":"St","year":"2013","journal-title":"Arthritis & Rheumatism"},{"issue":"2","key":"10.1016\/j.bcp.2025.117116_b0355","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/art.22536","article-title":"Improvement of Sj\u00f6gren's syndrome after two infusions of rituximab (anti\u2010CD20)","volume":"57","author":"Devauchelle-Pensec","year":"2007","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.bcp.2025.117116_b0360","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.clim.2017.05.002","article-title":"The value of rituximab treatment in primary Sj\u00f6gren's syndrome","volume":"182","author":"Verstappen","year":"2017","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117116_b0365","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3899\/jrheum.210441","article-title":"Long-term safety of rituximab in primary sj\u00f6gren syndrome: the experience of a single center","volume":"49","author":"Berardicurti","year":"2022","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2025.117116_b0370","article-title":"Rituximab therapy for primary Sj\u00f6gren\u2019s syndrome","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117116_b0375","article-title":"OP0135 safety and efficacy of subcutaneous belimumab and intravenous rituximab combination in patients with primary Sj\u00f6gren\u2019s syndrome: a phase 2, randomised, placebo-controlled 68-week study","author":"Mariette","year":"2021","journal-title":"BMJ Publishing Group Ltd"},{"issue":"3","key":"10.1016\/j.bcp.2025.117116_b0380","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/BOR.0000000000000491","article-title":"How does abatacept really work in rheumatoid arthritis?","volume":"30","author":"Bonelli","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117116_b0385","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sj\u00f6gren\u2019s syndrome: results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2025.117116_b0390","doi-asserted-by":"crossref","unstructured":"L. de Wolff, J.F. van Nimwegen, E. Mossel, G.S. van Zuiden, A.J. Stel, K.I. Majoor, L. Olie, L.I. Los, A. Vissink, F.K.L. Spijkervet, Long-term abatacept treatment for 48 weeks in patients with primary sj\u00f6gren's syndrome: the open-label extension phase of the ASAP-III trial, Elsevier, p. 151955.","DOI":"10.1016\/j.semarthrit.2022.151955"},{"key":"10.1016\/j.bcp.2025.117116_b0395","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: a review in systemic lupus erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"issue":"23","key":"10.1016\/j.bcp.2025.117116_b0400","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.bcp.2025.117116_b0405","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard-2023-224503","article-title":"Examining the biological pathways underlying clinical heterogeneity in Sjogren\u2019s syndrome: proteomic and network analysis","volume":"83","author":"Berry","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.bcp.2025.117116_b0410","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/13543784.2024.2312216","article-title":"New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology","volume":"33","author":"Zhou","year":"2024","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"1","key":"10.1016\/j.bcp.2025.117116_b0415","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/1744666X.2019.1544892","article-title":"Upadacitinib for the treatment of rheumatoid arthritis","volume":"15","author":"Serhal","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.bcp.2025.117116_b0420","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12016-020-08786-6","article-title":"JAK inhibitors: prospects in connective tissue diseases","volume":"59","author":"You","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9","key":"10.1016\/j.bcp.2025.117116_b0425","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/rheumatology\/keq158","article-title":"Psychopathological and personality features in primary Sj\u00f6gren\u2019s syndrome\u2014associations with autoantibodies to neuropeptides","volume":"49","author":"Karaiskos","year":"2010","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.bcp.2025.117116_b0430","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1084\/jem.20121878","article-title":"Blocking follistatin-like 1 attenuates bleomycin-induced pulmonary fibrosis in mice","volume":"212","author":"Dong","year":"2015","journal-title":"J. Exp. Med."},{"issue":"17","key":"10.1016\/j.bcp.2025.117116_b0435","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1080\/14656566.2021.1951224","article-title":"An update of targeted therapeutic options for primary Sj\u00f6gren syndrome: current status and future development","volume":"22","author":"Retamozo","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bcp.2025.117116_b0440","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fimmu.2013.00343","article-title":"Host factors and HIV-1 replication: clinical evidence and potential therapeutic approaches","volume":"4","author":"Santa-Marta","year":"2013","journal-title":"Front. Immunol."},{"issue":"23","key":"10.1016\/j.bcp.2025.117116_b0445","doi-asserted-by":"crossref","first-page":"9172","DOI":"10.3390\/ijms21239172","article-title":"Innate immunity and biological therapies for the treatment of Sj\u00f6gren\u2019s syndrome","volume":"21","author":"Srivastava","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117116_b0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2016.47","article-title":"Sj\u00f6gren syndrome","volume":"2","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/j.bcp.2025.117116_b0455","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/biom11020251","article-title":"The role of interferons in the pathogenesis of Sj\u00f6gren\u2019s syndrome and future therapeutic perspectives","volume":"11","author":"Del Papa","year":"2021","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.bcp.2025.117116_b0460","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/1529-0131(200103)44:3<638::AID-ANR112>3.0.CO;2-J","article-title":"Polymorphisms of the Ro52 gene associated with anti\u2013Ro 52\u2010kd autoantibodies in patients with primary Sj\u00f6gren's syndrome","volume":"44","author":"Nakken","year":"2001","journal-title":"Arthritis & Rheumatism"},{"issue":"10","key":"10.1016\/j.bcp.2025.117116_b0465","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.autrev.2018.05.005","article-title":"Clinical and immunological parameters of Sj\u00f6gren's syndrome","volume":"17","author":"Psianou","year":"2018","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"10.1016\/j.bcp.2025.117116_b0470","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/joim.13032","article-title":"Environmental factors in the pathogenesis of primary Sjogren's syndrome","volume":"287","author":"Bjork","year":"2020","journal-title":"J. Intern. Med."},{"issue":"4","key":"10.1016\/j.bcp.2025.117116_b0475","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The immunobiology of the interleukin-12 family: room for discovery","volume":"50","author":"Wojno","year":"2019","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.bcp.2025.117116_b0480","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1084\/jem.169.6.2191","article-title":"Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren's syndrome","volume":"169","author":"Saito","year":"1989","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.bcp.2025.117116_b0485","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W","article-title":"Infliximab in patients with primary Sj\u00f6gren's syndrome: a pilot study","volume":"44","author":"Steinfeld","year":"2001","journal-title":"Arthritis & Rheumatism"},{"issue":"7","key":"10.1016\/j.bcp.2025.117116_b0490","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sj\u00f6gren's syndrome: a twelve\u2010week randomized, double\u2010blind, placebo\u2010controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis & Rheumatism: Official Journal of the American College of Rheumatology"},{"issue":"1","key":"10.1016\/j.bcp.2025.117116_b0495","first-page":"96","article-title":"Etanercept in the treatment of patients with primary Sj\u00f6gren's syndrome: a pilot study","volume":"31","author":"Zandbelt","year":"2004","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117116_b0500","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1067\/moe.2003.30","article-title":"A pilot study to test the efficacy of oral administration of interferon-\u03b1 lozenges to patients with Sj\u00f6gren's syndrome","volume":"95","author":"Khurshudian","year":"2003","journal-title":"Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology"},{"issue":"7","key":"10.1016\/j.bcp.2025.117116_b0505","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.ophtha.2012.01.028","article-title":"Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1\/2 trial","volume":"119","author":"Liew","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.bcp.2025.117116_b0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren's syndrome\u2013a double blind, randomised clinical trial","volume":"7","author":"Norheim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.117116_b0515","article-title":"Tocilizumab for refractory organising pneumonia associated with Sj\u00f6gren's disease","author":"Justet","year":"2015","journal-title":"Case Reports"},{"key":"10.1016\/j.bcp.2025.117116_b0520","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jaut.2013.02.001","article-title":"Sj\u00f6gren's syndrome and the epithelial target: a comprehensive review","volume":"42","author":"Barrera","year":"2013","journal-title":"J. Autoimmun."},{"issue":"6","key":"10.1016\/j.bcp.2025.117116_b0525","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41584-021-00605-2","article-title":"Epithelial\u2013immune cell interplay in primary Sj\u00f6gren syndrome salivary gland pathogenesis","volume":"17","author":"Verstappen","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bcp.2025.117116_b0530","series-title":"The role of TH17 cells in a model of rheumatoid arthritis","author":"Patakas","year":"2011"},{"key":"10.1016\/j.bcp.2025.117116_b0535","doi-asserted-by":"crossref","unstructured":"N. Holdgate, E.W.S. Clair, Recent advances in primary Sjogren's syndrome, F1000Research 5 (2016).","DOI":"10.12688\/f1000research.8352.1"},{"issue":"10","key":"10.1016\/j.bcp.2025.117116_b0540","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3390\/cells12101359","article-title":"The role of regulatory T Cells in the onset and progression of primary Sj\u00f6gren\u2019s syndrome","volume":"12","author":"Blinova","year":"2023","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.bcp.2025.117116_b0545","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/1744666X.2018.1519396","article-title":"Interferon activation in primary Sj\u00f6gren\u2019s syndrome: recent insights and future perspective as novel treatment target","volume":"14","author":"Bodewes","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.bcp.2025.117116_b0550","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.935800","article-title":"SRSF1 acts as an IFN-I-regulated cellular dependency factor decisively affecting HIV-1 post-integration steps","volume":"13","author":"Sertznig","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2025.117116_b0555","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/bs.vh.2019.08.019","article-title":"Molecular aspects of aquaporins","volume":"113","author":"Li","year":"2020","journal-title":"Vitam. Horm."},{"issue":"11","key":"10.1016\/j.bcp.2025.117116_b0560","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.3390\/ijms19113392","article-title":"Involvement of aquaporins in the pathogenesis, diagnosis and treatment of Sj\u00f6gren\u2019s syndrome","volume":"19","author":"Soyfoo","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2025.117116_b0565","doi-asserted-by":"crossref","DOI":"10.1111\/eos.12969","article-title":"Molecular mechanisms of saliva secretion and hyposecretion","volume":"132","author":"Song","year":"2024","journal-title":"Eur. J. Oral Sci."},{"issue":"6","key":"10.1016\/j.bcp.2025.117116_b0570","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"issue":"Suppl 133","key":"10.1016\/j.bcp.2025.117116_b0575","doi-asserted-by":"crossref","first-page":"131","DOI":"10.55563\/clinexprheumatol\/fp741f","article-title":"Serum CXCL13, BAFF, IL-21 and IL-22 levels are related to disease activity and lymphocyte profile in primary Sj\u00f6gren\u2019s syndrome","volume":"39","author":"Loureiro-Amigo","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117116_b0580","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/cei.13242","article-title":"Activation of Toll-like receptor 7 signaling in labial salivary glands of primary Sj\u00f6gren's syndrome patients","volume":"196","author":"Shimizu","year":"2019","journal-title":"Clinical & Experimental Immunology"},{"issue":"3","key":"10.1016\/j.bcp.2025.117116_b0585","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/sji.12520","article-title":"Expression of Toll\u2010like receptors in peripheral blood mononuclear cells of patients with primary Sj\u00f6gren's syndrome","volume":"85","author":"Karlsen","year":"2017","journal-title":"Scand. J. Immunol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117116_b0590","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.40513","article-title":"Clinical efficacy and safety of baminercept, a lymphotoxin \u03b2 receptor fusion protein, in primary Sj\u00f6gren's syndrome: results from a phase II randomized, double\u2010blind, placebo\u2010controlled trial","volume":"70","author":"St","year":"2018","journal-title":"Arthritis & Rheumatology"},{"issue":"2","key":"10.1016\/j.bcp.2025.117116_b0595","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3390\/vaccines8020272","article-title":"Primary Sjogren syndrome: focus on innate immune cells and inflammation","volume":"8","author":"Rizzo","year":"2020","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.bcp.2025.117116_b0600","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s40001-024-01967-5","article-title":"Primary Sj\u00f6gren\u2019s syndrome: new perspectives on salivary gland epithelial cells","volume":"29","author":"Hou","year":"2024","journal-title":"Eur. J. Med. Res."},{"issue":"10","key":"10.1016\/j.bcp.2025.117116_b0605","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/14728222.2022.2157259","article-title":"Sj\u00f6gren\u2019s syndrome: shedding light on emerging and key drug targets","volume":"26","author":"Ridgewell","year":"2022","journal-title":"Expert Opin. Ther. Targets"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225003818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225003818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T13:29:42Z","timestamp":1767360582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225003818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":121,"alternative-id":["S0006295225003818"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117116","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced strategies for targeting molecular pathways in Sj\u00f6gren\u2019s syndrome","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117116"}}